Prescrire's rating
OFFERS AN ADVANTAGE Subcutaneous injection is quicker than intravenous administration. In Europe, this drug is restricted to hospital use. The harm-benefit balance of pertuzumab + trastuzumab is only favourable in women with inoperable breast cancer.
©Prescrire 1 May 2022
Source: "Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer" Prescrire International 2022; 31 (237): 123. Free.
Enjoy full access to Prescrire International, and support independent information
|